| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7459554 | ASTRAZENECA | Imidazopyrazine tyrosine kinase inhibitors |
Nov, 2026
(3 years from now) | |
| US9290504 | ASTRAZENECA | 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as Btk inhibitors |
Jul, 2032
(8 years from now) | |
| US11059829 | ASTRAZENECA | Crystal forms of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide maleate |
Jul, 2036
(12 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10239883 | ASTRAZENECA | 4-imidazopyridazin-1-yl-benzamides as BTK inhibitors |
Jul, 2032
(8 years from now) | |
| US9758524 | ASTRAZENECA | 4-imidazopyridazin-1-yl-benzamides as Btk inhibitors |
Jul, 2032
(8 years from now) | |
| US10272083 | ASTRAZENECA | Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor |
Jan, 2035
(11 years from now) | |
Calquence is owned by Astrazeneca.
Calquence contains Acalabrutinib Maleate.
Calquence has a total of 6 drug patents out of which 0 drug patents have expired.
Calquence was authorised for market use on 03 August, 2022.
Calquence is available in tablet;oral dosage forms.
Calquence can be used as treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy; treatment of adult patients with previously untreated chronic lymphocytic leukemia or small lymphocytic leukemia in combination with obinutuzumab; treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic leukemia; treatment of adult patients with previously untreated small lymphocytic leukemia in combination with obinutuzumab; treatment of adult patients with previously untreated chronic lymphocytic leukemia in combination with obinutuzumab; treatment of adult patients with small lymphocytic leukemia; treatment of adult patients with chronic lymphocytic leukemia, treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy, treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy by administering 100 mg of acalabrutinib twice daily; treatment of adult patients with chronic lymphocytic leukemia by administering 100mg of acalabrutinib twice daily; treatment of adult patients with small lymphocytic leukemia by administering 100mg of acalabrutinib twice daily; treatment of adult patients with previously untreated chronic lymphocytic leukemia by administering 100 mg of acalabrutinib twice daily in combination with obinutuzumab; treatment of adult patients with previously untreated small lymphocytic leukemia by administering 100 mg of acalabrutinib twice daily in combination with obinutuzumab; treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic leukemia by administering 100 mg of acalabrutinib twice daily; treatment of adult patients with previously untreated chronic lymphocytic leukemia or small lymphocytic leukemia in combination with obinutuzumab by administering 100 mg of acalabrutinib twice daily, treatment of adult patients with chronic lymphocytic leukemia; treatment of adult patients with previously untreated chronic lymphocytic leukemia in combination with obinutuzumab.
Drug patent challenges can be filed against Calquence from 2021-10-31.
The generics of Calquence are possible to be released after 01 July, 2036.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Oct 31, 2022 |
Drugs and Companies using ACALABRUTINIB MALEATE ingredient
NCE-1 date: 2021-10-31
Market Authorisation Date: 03 August, 2022
Treatment: Treatment of adult patients with chronic lymphocytic leukemia; Treatment of adult patients with previously untreated chronic lymphocytic leukemia in combination with obinutuzumab; Treatment of adult p...
Dosage: TABLET;ORAL
CALQUENCE family patents
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7459554 | ASTRAZENECA | Imidazopyrazine tyrosine kinase inhibitors |
Nov, 2026
(3 years from now) | |
| US9290504 | ASTRAZENECA | 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as Btk inhibitors |
Jul, 2032
(8 years from now) | |
| US9796721 | ASTRAZENECA | Crystal forms of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide |
Jul, 2036
(12 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9758524 | ASTRAZENECA | 4-imidazopyridazin-1-yl-benzamides as Btk inhibitors |
Jul, 2032
(8 years from now) | |
| US10239883 | ASTRAZENECA | 4-imidazopyridazin-1-yl-benzamides as BTK inhibitors |
Jul, 2032
(8 years from now) | |
| US10272083 | ASTRAZENECA | Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor |
Jan, 2035
(11 years from now) | |
| US10167291 | ASTRAZENECA | Pharmaceutical composition comprising a crystal form of (S)-4-(8-amino-3-(1-(but-2-ynoyl) pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide |
Jul, 2036
(12 years from now) | |
Calquence is owned by Astrazeneca.
Calquence contains Acalabrutinib.
Calquence has a total of 7 drug patents out of which 0 drug patents have expired.
Calquence was authorised for market use on 31 October, 2017.
Calquence is available in capsule;oral dosage forms.
Calquence can be used as treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy; treatment of adult patients with previously untreated small lymphocytic leukemia in combination with obinutuzumab; treatment of adult patients with previously untreated chronic lymphocytic leukemia or small lymphocytic leukemia in combination with obinutuzumab; treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic leukemia; treatment of adult patients with previously untreated chronic lymphocytic leukemia in combination with obinutuzumab; treatment of adult patients with chronic lymphocytic leukemia; treatment of adult patients with small lymphocytic leukemia, treatment of adult patients with previously untreated chronic lymphocytic leukemia in combination with obinutuzumab; treatment of adult patients with chronic lymphocytic leukemia, treatment of adult patients with small lymphocytic leukemia; treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic leukemia; treatment of adult patients with chronic lymphocytic leukemia; treatment of adult patients with previously untreated chronic lymphocytic leukemia in combination with obinutuzumab; treatment of adult patients with previously untreated small lymphocytic leukemia in combination with obinutuzumab; treatment of adult patients with previously untreated chronic lymphocytic leukemia or small lymphocytic leukemia in combination with obinutuzumab; treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy, treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy, treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy by administering 100 mg of acalabrutinib twice daily; treatment of adult patients with small lymphocytic leukemia by administering 100mg of acalabrutinib twice daily; treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic leukemia by administering 100 mg of acalabrutinib twice daily; treatment of adult patients with previously untreated chronic lymphocytic leukemia by administering 100 mg of acalabrutinib twice daily in combination with obinutuzumab; treatment of adult patients with previously untreated chronic lymphocytic leukemia or small lymphocytic leukemia in combination with obinutuzumab by administering 100 mg of acalabrutinib twice daily; treatment of adult patients with chronic lymphocytic leukemia by administering 100mg of acalabrutinib twice daily; treatment of adult patients with previously untreated small lymphocytic leukemia by administering 100 mg of acalabrutinib twice daily in combination with obinutuzumab.
The generics of Calquence are possible to be released after 01 July, 2036.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Nov 21, 2026 |
Drugs and Companies using ACALABRUTINIB ingredient
Market Authorisation Date: 31 October, 2017
Treatment: Treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy; Treatment of adult patients with previously untreated chronic lymphocytic leukemia in combination wi...
Dosage: CAPSULE;ORAL
CALQUENCE family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic